IL13RA2 and glioblastoma: In the CNS, circumventing the blood–brain barrier via intraventricular or intracavitary routes (e.g., Ommaya reservoir) has allowed for effective treatment of glioblastoma and leptomeningeal disease with IL-13Rα2 or B7-H3-targeted CAR T-cells, with some studies reporting complete lesion clearance and prolonged remission without grade ≥ 3 neurotoxicity (NCT02208362, NCT03500991).